ARAY(ARAY)
ARAY
Signal
Leaning Bearish1↑2↓
PRICE
Prev Close
0.28
Open
0.29
Day Range0.27 – 0.30
0.27
0.30
52W Range0.27 – 2.10
0.27
2.10
0% of range
VOLUME & SIZE
Avg Volume
2.0M
FUNDAMENTALS
P/E Ratio
-0.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.26
Market-like
Key MetricsTTM
Market Cap$32.12M
Revenue TTM$428.57M
Net Income TTM-$46.13M
Free Cash Flow-$28.95M
Gross Margin26.8%
Net Margin-10.8%
Operating Margin-3.5%
Return on Equity-77.5%
Return on Assets-10.3%
Debt / Equity4.37
Current Ratio1.42
EPS TTM$-0.37
ANALYST COVERAGE12 analysts
BUY
▲ +640.7%upside to target
Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 116 days
Sep 10
ARAY News
About
accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.
Sector
Industry
Surgical and Medical Instrument Manufacturing
CEO
Joshua Levine
Website
Seth BlacksburgSenior VP and Chief Medical & Marketing Officer
Ali PervaizSenior Vice President & Chief Financial Officer
David ShinSenior VP, Chief Legal Officer & Corporate Secretary
Jim DennisonSenior VP and Chief Quality & Regulatory Affairs Officer
John DunnSenior VP, Chief Information Officer
Leonel PeraltaSenior Vice President & Chief Operations Officer
Michael J. MurphyCorporate Controller & Principal Accounting Officer
Sandeep ChalkeSenior Vice President & Chief Commercial Officer
Stephen R. LaNevePresident, Chief Executive Officer & Director
Melanie RiversSenior Vice President, Chief Human Resources Officer
Beth KaplanPublic Relations Director
Xavier De MisouardPresident & GM of EIMEA Region